These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8628010)

  • 1. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity.
    Andrivon W; Saucier JM; Auclair C; Monneret C; Florent JC; Guillosson JJ; Nafziger J
    Leuk Res; 1996 Feb; 20(2):119-26. PubMed ID: 8628010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new anthracycline with potent antileukemic activity exhibits reduced mutagenicity.
    Andrivon W; Callais F; Nafziger J; Monneret C; Guillosson JJ
    Mutat Res; 1995 Oct; 344(3-4):135-40. PubMed ID: 7491131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity.
    Capranico G; Zunino F; Kohn KW; Pommier Y
    Biochemistry; 1990 Jan; 29(2):562-9. PubMed ID: 2154250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.
    Campbell KJ; O'Shea JM; Perkins ND
    BMC Cancer; 2006 Apr; 6():101. PubMed ID: 16630341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and physicochemical properties of a new anthracycline with potent antileukemic activity.
    Nafziger J; Auclair C; Florent JC; Guillosson JJ; Monneret C
    Leuk Res; 1991; 15(8):709-13. PubMed ID: 1654481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
    Capranico G; Butelli E; Zunino F
    Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
    Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
    Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety.
    Ciesielska E; Studzian K; Wasowska M; Oszczapowicz I; Szmigiero L
    Cell Biol Toxicol; 2005; 21(3-4):139-47. PubMed ID: 16328893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of structural modifications of daunorubicin on in vitro antileukemic activity.
    Stojak M; Mazur L; Opydo-Chanek M; Lukawska M; Oszczapowicz I
    Anticancer Res; 2012 Dec; 32(12):5271-7. PubMed ID: 23225426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhibition of topoisomerase I by DNA-binding agents.
    Crow RT; Crothers DM
    J Med Chem; 1994 Sep; 37(19):3191-4. PubMed ID: 7932544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
    Zunino F; Capranico G
    Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
    Gewirtz DA
    Biochem Pharmacol; 1999 Apr; 57(7):727-41. PubMed ID: 10075079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
    De Graff WG; Myers LS; Mitchell JB; Hahn SM
    Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Structure and activity of anthracyclines].
    Lavelle F
    Pathol Biol (Paris); 1987 Jan; 35(1):11-9. PubMed ID: 3550604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity and inhibitory properties against topoisomerase II of doxorubicin and its formamidine derivatives.
    Kik K; Studzian K; Wasowska-Łukawska M; Oszczapowicz I; Szmigiero L
    Acta Biochim Pol; 2009; 56(1):135-42. PubMed ID: 19238256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of a new bisintercalating anthracycline antibiotic.
    Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
    J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
    Willmore E; Errington F; Tilby MJ; Austin CA
    Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.
    Capranico G; Soranzo C; Zunino F
    Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.